Skip to main content

Peer Review reports

From: Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

Original Submission
12 Oct 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
13 Feb 2023 Reviewed Reviewer Report
14 Feb 2023 Reviewed Reviewer Report
14 May 2023 Reviewed Reviewer Report - Rajesh Kar
2 Jun 2023 Author responded Author comments - Zhiyang Li
Resubmission - Version 3
2 Jun 2023 Submitted Manuscript version 3
21 Jun 2023 Reviewed Reviewer Report
26 Jun 2023 Reviewed Reviewer Report
11 Jul 2023 Author responded Author comments - Zhiyang Li
Resubmission - Version 4
11 Jul 2023 Submitted Manuscript version 4
28 Jul 2023 Author responded Author comments - Zhiyang Li
Resubmission - Version 5
28 Jul 2023 Submitted Manuscript version 5
19 Aug 2023 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
20 Aug 2023 Editorially accepted
31 Aug 2023 Article published 10.1186/s12885-023-11322-2

You can find further information about peer review here.

Back to article page